Journal News

New biomarker offers hope for earlier ovarian cancer detection

Rob Mitchum
By Rob Mitchum
Aug. 26, 2023

Ovarian cancer is particularly difficult to detect, as the disease often does not produce significant symptoms until it has reached late stages and caused metastasis. New screening methods would help physicians detect ovarian tumors early and dramatically increase the chances of patient survival. 

A study published in Molecular & Cellular Proteomics by past and current University of Illinois Chicago faculty members used a variety of cutting-edge techniques to identify a new biomarker for ovarian cancer that offers hope for effective routine screening — potentially even at home.

This is the graphical abstract for the article "An integrated approach to protein discovery and detection from complex biofluids."

While biomarker studies often seek signs of tumor DNA in blood, the research groups of Joanna Burdette, professor of pharmaceutical sciences at the UIC College of Pharmacy, and Laura Sanchez, who moved from UIC to University of California Santa Cruz in 2021, instead looked to the microenvironment near potential tumors.

Researchers collected vaginal samples from mice with ovarian tumors, then used multiple methods such as mass spectrometry — experiments conducted with Stephanie Cologna, UIC associate professor of chemistry — and proteomics technology to find a molecular “fingerprint” of the cancer. The tests identified a potential biomarker in the enzyme cystatin A, which has been previously associated with the body’s immune response to cancer, not the tumor itself.

“I think that’s going to be a very important thing to think about because if we want to detect tumors early, they should be small, maybe even so small that they wouldn’t be detectable if you were just looking for the cancer cell,” said Burdette, who is also a member of the University of Illinois Cancer Center. “But if you look in the environment around the tumor, the immune system, bacteria and other things responding to it, that might be a more robust signal that we could detect earlier.”

The researchers then tested this signal in samples from human patients, using tampons worn by women the day before gynecologic surgery. In samples from patients diagnosed with ovarian cancer, they found that cystatin A levels were twice as high as in the samples diagnosed as benign.

While further trials are needed to verify the predictive power of cystatin A in humans, the paper provides proof of concept that this approach can identify potential biomarkers detectable through routine procedures. Gynecologists could collect vaginal samples during regular checkups or, more speculatively, women could send tampons for laboratory screening on a variety of concerns, similar to new home-screening tests for colon cancer. 

“The idea that you could slot this in as part of a routine gynecological exam makes sense to us,” Burdette said. “We can imagine these fingerprints are probably not unique to just cancer, they could also be useful for a variety of women’s health issues, such as vaginal infection, cervical cancer and STDs.”

This article first appeared in UIC Today. Read the original.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Rob Mitchum
Rob Mitchum

Rob Mitchum is director of research and scienc communications at the University of Illinois Chicago. Previously, he was associate director of communications for data science and computing at the University of Chicago, where he led communications for the computer science department and Data Science Institute. He also held communications roles at the University of Chicago with the Center for Data and Computing, the Computation Institute and UChicago Medicine. He received his Ph.D. in neurobiology from the University of Chicago in 2007. He spent two years as a journalist with the Chicago Tribune, covering science and general assignment topics. He also has written about music for publications including Pitchfork, Uncut, Paste, Esquire, Deadspin and Relix.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

From lab to land: Crop modifications are fortifying our food supply against climate change
News

From lab to land: Crop modifications are fortifying our food supply against climate change

Nov. 13, 2024

Scientists explore genetic and biochemical innovations fueling future-proofing agriculture

Join the pioneers of ferroptosis at cell death conference
In-person Conference

Join the pioneers of ferroptosis at cell death conference

Nov. 13, 2024

Meet Brent Stockwell, Xuejun Jiang and Jin Ye — the co-chairs of the ASBMB’s 2025 meeting on metabolic cross talk and biochemical homeostasis research.

How antioxidant-enhanced ice cream is changing the game for frozen treats
News

How antioxidant-enhanced ice cream is changing the game for frozen treats

Nov. 12, 2024

University of Wisconsin scientists create a sweet treat with more nutrients and better stability using tannins

Helping underrepresented scientists feel seen
Award

Helping underrepresented scientists feel seen

Nov. 12, 2024

Benjamin Garcia will receive the ASBMB Ruth Kirschstein Diversity in Science Award at the ASBMB Annual meeting, April 12–15 in Chicago.

Plants get a GMO glow-up
News

Plants get a GMO glow-up

Nov. 10, 2024

Lose the prickles. Add bioluminescence. Up the nutrients without the bitter flavor. CRISPR gene editing is opening a new world of genetically modified plants for home growers.

Bananapocalypse – the tricky genetics of a devastating fungus
News

Bananapocalypse – the tricky genetics of a devastating fungus

Nov. 9, 2024

Fusarium oxysporum can infect over 120 plant species. Whether it destroys Cavendish bananas as it did their predecessor depends on the agricultural industry and consumers.